S&P 500   3,337.75 (-1.05%)
DOW   28,992.41 (-0.78%)
QQQ   230.27 (-1.92%)
AAPL   313.05 (-2.26%)
FB   210.18 (-2.05%)
MSFT   178.59 (-3.16%)
GOOGL   1,483.46 (-2.21%)
AMZN   2,095.97 (-2.65%)
CGC   21.88 (-1.93%)
NVDA   294.07 (-4.74%)
BABA   212.59 (-2.50%)
MU   56.99 (-3.41%)
GE   12.25 (-2.23%)
TSLA   901.00 (+0.18%)
AMD   53.28 (-6.97%)
T   38.55 (-0.16%)
ACB   1.67 (-0.60%)
F   7.89 (-1.74%)
NFLX   380.07 (-1.54%)
PRI   132.33 (-2.98%)
BAC   34.36 (-1.41%)
DIS   138.97 (-1.00%)
GILD   69.70 (+4.03%)
S&P 500   3,337.75 (-1.05%)
DOW   28,992.41 (-0.78%)
QQQ   230.27 (-1.92%)
AAPL   313.05 (-2.26%)
FB   210.18 (-2.05%)
MSFT   178.59 (-3.16%)
GOOGL   1,483.46 (-2.21%)
AMZN   2,095.97 (-2.65%)
CGC   21.88 (-1.93%)
NVDA   294.07 (-4.74%)
BABA   212.59 (-2.50%)
MU   56.99 (-3.41%)
GE   12.25 (-2.23%)
TSLA   901.00 (+0.18%)
AMD   53.28 (-6.97%)
T   38.55 (-0.16%)
ACB   1.67 (-0.60%)
F   7.89 (-1.74%)
NFLX   380.07 (-1.54%)
PRI   132.33 (-2.98%)
BAC   34.36 (-1.41%)
DIS   138.97 (-1.00%)
GILD   69.70 (+4.03%)
S&P 500   3,337.75 (-1.05%)
DOW   28,992.41 (-0.78%)
QQQ   230.27 (-1.92%)
AAPL   313.05 (-2.26%)
FB   210.18 (-2.05%)
MSFT   178.59 (-3.16%)
GOOGL   1,483.46 (-2.21%)
AMZN   2,095.97 (-2.65%)
CGC   21.88 (-1.93%)
NVDA   294.07 (-4.74%)
BABA   212.59 (-2.50%)
MU   56.99 (-3.41%)
GE   12.25 (-2.23%)
TSLA   901.00 (+0.18%)
AMD   53.28 (-6.97%)
T   38.55 (-0.16%)
ACB   1.67 (-0.60%)
F   7.89 (-1.74%)
NFLX   380.07 (-1.54%)
PRI   132.33 (-2.98%)
BAC   34.36 (-1.41%)
DIS   138.97 (-1.00%)
GILD   69.70 (+4.03%)
S&P 500   3,337.75 (-1.05%)
DOW   28,992.41 (-0.78%)
QQQ   230.27 (-1.92%)
AAPL   313.05 (-2.26%)
FB   210.18 (-2.05%)
MSFT   178.59 (-3.16%)
GOOGL   1,483.46 (-2.21%)
AMZN   2,095.97 (-2.65%)
CGC   21.88 (-1.93%)
NVDA   294.07 (-4.74%)
BABA   212.59 (-2.50%)
MU   56.99 (-3.41%)
GE   12.25 (-2.23%)
TSLA   901.00 (+0.18%)
AMD   53.28 (-6.97%)
T   38.55 (-0.16%)
ACB   1.67 (-0.60%)
F   7.89 (-1.74%)
NFLX   380.07 (-1.54%)
PRI   132.33 (-2.98%)
BAC   34.36 (-1.41%)
DIS   138.97 (-1.00%)
GILD   69.70 (+4.03%)
Log in

NYSE:TAK - Takeda Pharmaceutical Stock Price, Forecast & News

$18.79
+0.22 (+1.18 %)
(As of 02/21/2020 04:00 PM ET)
Today's Range
$18.68
Now: $18.79
$18.84
50-Day Range
$18.57
MA: $19.77
$20.31
52-Week Range
$16.10
Now: $18.79
$21.61
Volume890,600 shs
Average Volume1.20 million shs
Market Capitalization$58.57 billion
P/E Ratio72.27
Dividend Yield3.23%
Beta0.89
Takeda Pharmaceutical Company Limited, together with its subsidiaries, engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. The company provides medicines in various therapeutic areas comprising gastroenterology, oncology, and neuroscience; and vaccines. It operates in Japan, the United States, Europe and Canada, Russia/CIS, Latin America, Asia, the Middle East, Oceania, and Africa. The company has a collaboration agreement with Lupus Therapeutics Inc. to evaluate the investigational biologic TAK-079 as a potential new therapy for Lupus in a Phase 1 trial. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone813-3278-2306

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$18.88 billion
Cash Flow$2.17 per share
Book Value$14.39 per share

Profitability

Net Income$982.13 million

Miscellaneous

Employees49,578
Outstanding Shares3,117,140,000
Market Cap$58.57 billion
Next Earnings Date5/12/2020 (Estimated)
OptionableOptionable

Receive TAK News and Ratings via Email

Sign-up to receive the latest news and ratings for TAK and its competitors with MarketBeat's FREE daily newsletter.


Takeda Pharmaceutical (NYSE:TAK) Frequently Asked Questions

What is Takeda Pharmaceutical's stock symbol?

Takeda Pharmaceutical trades on the New York Stock Exchange (NYSE) under the ticker symbol "TAK."

How were Takeda Pharmaceutical's earnings last quarter?

Takeda Pharmaceutical Co Ltd (NYSE:TAK) released its quarterly earnings data on Tuesday, February, 4th. The company reported $0.53 EPS for the quarter. The firm had revenue of $7.90 billion for the quarter. Takeda Pharmaceutical had a net margin of 2.25% and a return on equity of 13.17%. View Takeda Pharmaceutical's Earnings History.

When is Takeda Pharmaceutical's next earnings date?

Takeda Pharmaceutical is scheduled to release their next quarterly earnings announcement on Tuesday, May 12th 2020. View Earnings Estimates for Takeda Pharmaceutical.

What guidance has Takeda Pharmaceutical issued on next quarter's earnings?

Takeda Pharmaceutical updated its FY 2019 Pre-Market earnings guidance on Tuesday, February, 4th. The company provided EPS guidance of 3.53-3.72 for the period. The company issued revenue guidance of $30.147-30.147 billion.

What price target have analysts set for TAK?

4 Wall Street analysts have issued 1-year target prices for Takeda Pharmaceutical's stock. Their forecasts range from $19.50 to $19.50. On average, they expect Takeda Pharmaceutical's share price to reach $19.50 in the next year. This suggests a possible upside of 3.8% from the stock's current price. View Analyst Price Targets for Takeda Pharmaceutical.

What is the consensus analysts' recommendation for Takeda Pharmaceutical?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Takeda Pharmaceutical in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Takeda Pharmaceutical.

Has Takeda Pharmaceutical been receiving favorable news coverage?

News articles about TAK stock have trended somewhat negative on Friday, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Takeda Pharmaceutical earned a news impact score of -1.0 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for Takeda Pharmaceutical.

Who are some of Takeda Pharmaceutical's key competitors?

What other stocks do shareholders of Takeda Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Takeda Pharmaceutical investors own include Alibaba Group (BABA), Verizon Communications (VZ), Cisco Systems (CSCO), CVS Health (CVS), Johnson & Johnson (JNJ), Procter & Gamble (PG), Home Depot (HD), The Coca-Cola (KO), NVIDIA (NVDA) and Abbott Laboratories (ABT).

Who are Takeda Pharmaceutical's key executives?

Takeda Pharmaceutical's management team includes the folowing people:
  • Mr. Christophe Weber, Pres, CEO & Representative Director (Age 53)
  • Dr. Andrew S. Plump, Chief Medical & Scientific Officer and Director (Age 54)
  • Dr. Seigo Izumo M.D., Chair of Management Board
  • Mr. Costa Saroukos, Chief Financial Officer (Age 48)
  • Mr. Haruhiko Hirate, Member of Management Board & Corp. Communications and Public Affairs Officer (Age 62)

Who are Takeda Pharmaceutical's major shareholders?

Takeda Pharmaceutical's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Adelphi Capital LLP (0.29%), Bank of America Corp DE (0.13%), First Trust Advisors LP (0.07%), Renaissance Technologies LLC (0.06%), Goldman Sachs Group Inc. (0.06%) and Brandes Investment Partners LP (0.05%).

Which institutional investors are selling Takeda Pharmaceutical stock?

TAK stock was sold by a variety of institutional investors in the last quarter, including Marshall Wace LLP, UBS Asset Management Americas Inc., TIG Advisors LLC, Janus Henderson Group PLC, Franklin Resources Inc., Marshall Wace North America L.P., Brandes Investment Partners LP and Jane Street Group LLC.

Which institutional investors are buying Takeda Pharmaceutical stock?

TAK stock was purchased by a variety of institutional investors in the last quarter, including Ovata Capital Management Ltd, Renaissance Technologies LLC, Raymond James & Associates, TD Asset Management Inc., Blueshift Asset Management LLC, Van ECK Associates Corp, Eagle Global Advisors LLC and Magnetar Financial LLC.

How do I buy shares of Takeda Pharmaceutical?

Shares of TAK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Takeda Pharmaceutical's stock price today?

One share of TAK stock can currently be purchased for approximately $18.79.

How big of a company is Takeda Pharmaceutical?

Takeda Pharmaceutical has a market capitalization of $58.57 billion and generates $18.88 billion in revenue each year. The company earns $982.13 million in net income (profit) each year or $0.51 on an earnings per share basis. Takeda Pharmaceutical employs 49,578 workers across the globe.View Additional Information About Takeda Pharmaceutical.

What is Takeda Pharmaceutical's official website?

The official website for Takeda Pharmaceutical is http://www.takeda.com/.

How can I contact Takeda Pharmaceutical?

Takeda Pharmaceutical's mailing address is 1-1 Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo M0, 103-8668. The company can be reached via phone at 813-3278-2306.


MarketBeat Community Rating for Takeda Pharmaceutical (NYSE TAK)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  78 (Vote Outperform)
Underperform Votes:  101 (Vote Underperform)
Total Votes:  179
MarketBeat's community ratings are surveys of what our community members think about Takeda Pharmaceutical and other stocks. Vote "Outperform" if you believe TAK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TAK will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/21/2020 by MarketBeat.com Staff

Featured Article: What is a capital gain?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel